US: 800.298.5699
Int'l: +1.240.747.3093
 
Matching geography
Reports matching your search in:
 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!
 

Prescription Drugs: market research reports

RSS Feeds

Prescription Drugs market research reports and industry analysis

  2    4  5  6  7  8  9  10  
Spain Pharmaceuticals and Healthcare Report Q2 2014
3/26/2014 | published by: Business Monitor International
... flow troublesand aggressive fiscal austerity measures, which focus heavily on cost containment in the healthcare sector,will continue to negatively impact pharmaceutical companies operating in Spain. Headline Expenditure Projections Pharmaceuticals: EUR24.09bn (US$31.79bn) in 2013 to EUR22.81bn ...  |  read more...
$1,295.00
Physician Views: Life-cycle management strategies in multiple sclerosis – can new versions of Copaxone, Avonex drive market share retention?
3/26/2014 | published by: FirstWord
... Teva and Biogen Idec, respectively, in 2013, it is not surprising to see both companies implementing life-cycle management strategies in the key US market. The performance of the two products has been shaped by the ...  |  read more...
$645.00
China Pharmaceuticals and Healthcare Report Q2 2014
3/26/2014 | published by: Business Monitor International
... and healthcare market. We continue to maintain this view, in light of supportive government policies and positive population dynamics. Headline Expenditure Projections Pharmaceuticals: CNY532.4bn (US$86.6bn) in 2013 to CNY610.8bn (US$99.7bn) in 2014; +14.7% inlocal currency ...  |  read more...
$1,295.00
Indonesia Pharmaceuticals and Healthcare Report Q2 2014
3/26/2014 | published by: Business Monitor International
... rollout of the scheme will be challenging, given logistical and human resources issuesin the country. We also note that while companies can expect to generate revenues as a result of thescheme's rollout, the operating environment ...  |  read more...
$1,295.00
Qatar Pharmaceuticals and Healthcare Report Q2 2014
3/26/2014 | published by: Business Monitor International
... Summit for Health(WISH). Experts assessed the gap between the perceived requirements for the dissemination of informationand the reality in each country: only in Qatar did the reality match the experts' ratings. Qatar's healthcaresystem is set ...  |  read more...
$1,295.00
Egypt Pharmaceuticals and Healthcare Report Q2 2014
3/19/2014 | published by: Business Monitor International
... some localdrug production, ongoing strikes by doctors and calls for improvements to the registration and pricingregime for pharmaceuticals. Despite its favourable demographic and epidemiological profile, the Egyptianpharmaceutical market has a relatively weak outlook for growth, ...  |  read more...
$1,295.00
Finland Pharmaceuticals and Healthcare Report Q2 2014
3/19/2014 | published by: Business Monitor International
... to multinational drugmakers due to its excellent regulatory environment, ageing population andpreference for patented medicines. Headline Expenditure Projections Pharmaceuticals: EUR2.96bn (US$3.91bn) in 2013 to EUR3.02bn (US$3.83bn) in 2014;+1.8% in localcurrency terms and -2.1% in US ...  |  read more...
$1,295.00
India Pharmaceuticals and Healthcare Report Q2 2014
3/19/2014 | published by: Business Monitor International
... industry,following the implementation of the Drug Price Control Order in May 2013. While we forecast stronggrowth for the sector in 2014, persisting issues such as the halting of clinical trials, low healthcareexpenditure and company-specific manufacturing ...  |  read more...
$1,295.00
Ireland Pharmaceuticals and Healthcare Report Q2 2014
3/19/2014 | published by: Business Monitor International
... EUR85bn bailout with theEU/IMF in December 2013, the governing Fine Gael/Labour coalition will persevere with austeritymeasures. Pharmaceutical companies operating in Ireland therefore face significant downside risk,illustrated by a number of multinationals' recent withdrawals from the ...  |  read more...
$1,295.00
The Chinese Pharmaceutical Market to 2024 - Commercial & Strategic developments in the Chinese Pharmaceutical Market to 2024
3/19/2014 | published by: GMR Data Ltd.
... develop Chinese products Establish anti-counterfeiting systems today to increase market size and revenue From 2008 to 2013, China’s OTC drugs market reported an average growth of 15% with the market reaching $20.6bn in 2013 up ...  |  read more...
$2,450.00
Switzerland Pharmaceuticals and Healthcare Report Q2 2014
3/19/2014 | published by: Business Monitor International
... into greater demand for drugs. Furthermore, the country's highly developed infrastructuremeans that access to healthcare is easy, further supporting the consumption of medicines. Headline Expenditure Projections Pharmaceuticals: CHF7.19bn (US$7.76bn) in 2013 to CHF7.33bn (US$6.84bn) in ...  |  read more...
$1,295.00
Belarus Pharmaceuticals and Healthcare Report Q2 2014
3/19/2014 | published by: Business Monitor International
... devaluation temporarily relents. However, Belarus must now contend with the consequences of Ukrainian instability and the impact of thison the region's economies. There are significant downside risks to our forecast for 2014, due to the ...  |  read more...
$1,295.00
Brazil Pharmaceuticals and Healthcare Report Q2 2014
3/19/2014 | published by: Business Monitor International
... opportunities for drugmakers and healthcare serviceproviders. However, given the Brazilian government's protectionist measures in the pharmaceutical sector,we believe local drugmakers will outpace multinationals. Headline Expenditure Projections Pharmaceuticals: BRL57.0bn (US$26.4bn) in 2013 to BRL61.6bn (US$26.2bn) in ...  |  read more...
$1,295.00
Chile Pharmaceuticals and Healthcare Report Q2 2014
3/19/2014 | published by: Business Monitor International
... the country. The tightenedbioequivalent regulations will boost genuine medicine sales and force similares out of the market. However,we believe the current lack of vigilance in bioequivalence regulations in Chile has allowed the proliferationof low quality ...  |  read more...
$1,295.00
Iran Pharmaceuticals and Healthcare Report Q2 2014
3/19/2014 | published by: Business Monitor International
... the rial means thatwe expect the value of the market in US dollar terms to contract sharply. On a positive note, improvedinternational relations have reduced the political risk associated with operating in the market formultinational ...  |  read more...
$1,295.00
Israel Pharmaceuticals and Healthcare Report Q2 2014
3/19/2014 | published by: Business Monitor International
... need for specialtytreatments, thereby capitalising on the country's strong academic research infrastructure. Favourablefactors include high per capita spending on medicines, a market size approaching US$2bn, a highproportion of pensioners and a largely urbanised population. However, ...  |  read more...
$1,295.00
Kuwait Pharmaceuticals and Healthcare Report Q2 2014
3/19/2014 | published by: Business Monitor International
... thoroughlyscrutinised. New hospitals are being planned for expatriate workers and infrastructure development willcontinue to be a key area of growth, in addition to opportunities for private healthcare insurance providersto serve the expatriate market. The government's ...  |  read more...
$1,295.00
Malaysia Pharmaceuticals and Healthcare Report Q2 2014
3/19/2014 | published by: Business Monitor International
... country's private healthcare sector is attracting foreign investment and development, whichsupports the growing medical tourism market. However, the shortage of specialist medical staff and thesignificant presence of counterfeit drugs are issues the country must overcome ...  |  read more...
$1,295.00
Portugal Pharmaceuticals and Healthcare Report Q2 2014
3/19/2014 | published by: Business Monitor International
... consumer spending. Thehealthcare budget will continue to be slashed in 2014; the authorities have to make further cuts inreimbursement; and reference prices are continually pushed downwards. The few opportunities for growthare being taken by manufactures ...  |  read more...
$1,295.00
Bangladesh Pharmaceuticals and Healthcare Report Q2 2014
3/12/2014 | published by: Business Monitor International
... -pocket -highlighting the low affordability of high-value pharmaceuticals and sophisticated healthcare treatments. Headline Expenditure Projections Pharmaceuticals: BDT138.81bn (US$1.78bn) in 2013 to BDT154.74bn (US$1.99bn) in 2014; +11.5%in local currency terms and +12.1% in US dollar terms ...  |  read more...
$1,295.00
France Pharmaceuticals and Healthcare Report Q2 2014
3/12/2014 | published by: Business Monitor International
... in the healthcare system.However, we question the strength of this legislation, as development and manufacturing costs for theseproducts are high and therefore actual cost savings secured through biosimilars may ultimately be limited. Furthermore, ongoing safety ...  |  read more...
$1,295.00
Peru Pharmaceuticals and Healthcare Report Q2 2014
3/12/2014 | published by: Business Monitor International
... companies can generate rapid sales growth due to the lack of mandatory medicine pricingsystem in Peru. More stringent quality controls, relatively weak domestic pharmaceutical industry, ongoingliberalisation of bilateral trade agreements and the recognition of 'High ...  |  read more...
$1,295.00
Uganda Pharmaceuticals and Healthcare Report Q2 2014
3/12/2014 | published by: Business Monitor International
... will beslow due to the limited capabilities of local pharmaceutical companies, which are unable to compete withthe greater range of medicines made by multinational generic drugmakers. Headline Expenditure Projections Pharmaceuticals: UGX824.35bn (US$320mn) in 2013 to ...  |  read more...
$1,295.00
Zimbabwe Pharmaceuticals and Healthcare Report Q2 2014
3/12/2014 | published by: Business Monitor International
... lack ofaccess to medical treatment has led to a large proportion of the population becoming more reliant onherbal and traditional medicine, which has seen a recent influx in the country. However, with theZimbabwean authorities pushing ...  |  read more...
$1,295.00
Belgium Pharmaceuticals and Healthcare Report Q2 2014
3/12/2014 | published by: Business Monitor International
... multinational firms. Even though per capitaspending on pharmaceuticals is relatively high, it is subjected to continual downward pressure - creatingopportunities for growth for manufacturers of generic drugs. In other words, economic agendas mean thatthe government ...  |  read more...
$1,295.00
  2    4  5  6  7  8  9  10  
 
Our Clients